Zoetis Inc. (NYSE:ZTS) Stake Lessened by Algert Global LLC

Algert Global LLC lessened its stake in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 61.8% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 9,425 shares of the company's stock after selling 15,251 shares during the period. Algert Global LLC's holdings in Zoetis were worth $1,536,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also made changes to their positions in ZTS. Mission Wealth Management LP raised its position in Zoetis by 2.0% in the 4th quarter. Mission Wealth Management LP now owns 2,938 shares of the company's stock worth $479,000 after purchasing an additional 59 shares during the period. VeraBank N.A. raised its holdings in shares of Zoetis by 4.1% during the fourth quarter. VeraBank N.A. now owns 1,562 shares of the company's stock worth $254,000 after purchasing an additional 62 shares during the last quarter. HUB Investment Partners LLC grew its position in Zoetis by 4.7% during the fourth quarter. HUB Investment Partners LLC now owns 1,373 shares of the company's stock valued at $224,000 after buying an additional 62 shares during the period. Procyon Advisors LLC grew its position in Zoetis by 1.4% during the fourth quarter. Procyon Advisors LLC now owns 4,712 shares of the company's stock valued at $768,000 after buying an additional 63 shares during the period. Finally, Coppell Advisory Solutions LLC grew its position in shares of Zoetis by 18.0% in the fourth quarter. Coppell Advisory Solutions LLC now owns 420 shares of the company's stock valued at $68,000 after purchasing an additional 64 shares during the period. Institutional investors own 92.80% of the company's stock.

Insider Activity at Zoetis

In related news, EVP Roxanne Lagano sold 326 shares of the business's stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $170.00, for a total value of $55,420.00. Following the completion of the sale, the executive vice president now directly owns 15,781 shares in the company, valued at approximately $2,682,770. The trade was a 2.02% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Willie M. Reed sold 1,210 shares of Zoetis stock in a transaction that occurred on Tuesday, March 11th. The shares were sold at an average price of $166.14, for a total transaction of $201,029.40. Following the transaction, the director now directly owns 11,245 shares in the company, valued at approximately $1,868,244.30. This trade represents a 9.71% decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.18% of the stock is owned by corporate insiders.

Zoetis Stock Performance

ZTS stock traded down $1.49 on Tuesday, hitting $160.43. The company's stock had a trading volume of 3,336,674 shares, compared to its average volume of 2,501,661. The firm has a 50 day moving average of $157.17 and a two-hundred day moving average of $165.83. Zoetis Inc. has a 1 year low of $139.70 and a 1 year high of $200.33. The stock has a market cap of $71.58 billion, a price-to-earnings ratio of 29.33, a price-to-earnings-growth ratio of 2.78 and a beta of 0.94. The company has a current ratio of 1.75, a quick ratio of 1.08 and a debt-to-equity ratio of 1.09.

Zoetis (NYSE:ZTS - Get Free Report) last announced its quarterly earnings data on Tuesday, May 6th. The company reported $1.48 EPS for the quarter, topping analysts' consensus estimates of $1.40 by $0.08. The company had revenue of $2.22 billion during the quarter, compared to the consensus estimate of $2.20 billion. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. Zoetis's quarterly revenue was up 1.4% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.38 EPS. Equities analysts predict that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Analysts Set New Price Targets

ZTS has been the topic of a number of analyst reports. Stifel Nicolaus reduced their target price on shares of Zoetis from $180.00 to $165.00 and set a "buy" rating on the stock in a research note on Monday, April 14th. Barclays boosted their price target on shares of Zoetis from $242.00 to $244.00 and gave the company an "overweight" rating in a research note on Friday, February 14th. StockNews.com raised shares of Zoetis from a "hold" rating to a "buy" rating in a research note on Friday, March 7th. UBS Group reduced their price target on shares of Zoetis from $189.00 to $170.00 and set a "neutral" rating on the stock in a research note on Wednesday, May 7th. Finally, Morgan Stanley reduced their price target on shares of Zoetis from $243.00 to $238.00 and set an "overweight" rating on the stock in a research note on Friday, February 14th. One equities research analyst has rated the stock with a hold rating, eight have given a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus price target of $212.75.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.